Current concepts: An HIV vaccine - Evolving concepts

[11] Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection [J]. NATURE, 1997, 387 (6629) : 183 - 188

[12] Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) : 8869 - 8873

[13] IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J]. SCIENCE, 1995, 270 (5243) : 1811 - 1815

[14] HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) : 15109 - 15114

[15] HIV vaccines: New frontiers in vaccine development [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : 500 - 511

[16] Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits [J]. BULLETIN OF MATHEMATICAL BIOLOGY, 2006, 68 (03) : 577 - 614

[17] HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges [J]. VIROLOGY, 2006, 352 (01) : 216 - 225

[18] Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404

[19] Follmann D., 2006, J ACQ IMMUN DEF SYND, V44, P49

[20] Estimating the benefit of an HIV-1 vaccine that reduces viral load set point [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (04) : 546 - 550

[11] Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection [J]. NATURE, 1997, 387 (6629) : 183 - 188

[12] Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) : 8869 - 8873

[13] IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J]. SCIENCE, 1995, 270 (5243) : 1811 - 1815

[14] HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) : 15109 - 15114

[15] HIV vaccines: New frontiers in vaccine development [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : 500 - 511

[16] Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits [J]. BULLETIN OF MATHEMATICAL BIOLOGY, 2006, 68 (03) : 577 - 614

[17] HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges [J]. VIROLOGY, 2006, 352 (01) : 216 - 225

[18] Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404

[19] Follmann D., 2006, J ACQ IMMUN DEF SYND, V44, P49

[20] Estimating the benefit of an HIV-1 vaccine that reduces viral load set point [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (04) : 546 - 550